Skip to main content

Nanobiotix S.A. (NBTX)

NASDAQ: NBTX · IEX Real-Time Price · USD
12.52 -0.52 (-3.99%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap459.70M
Revenue (ttm)2.38M
Net Income (ttm)n/a
Shares Out34.83M
EPS (ttm)-1.67
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume524
Open12.40
Previous Close13.04
Day's Range12.52 - 13.20
52-Week Range10.51 - 21.55
Beta2.28
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About NBTX

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. The company develops NanoXray products to help patients receiving radiotherapy by enhancing the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a sterile aqueous suspension of functionalized crystalline hafnium oxide nanoparticles used for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pa...

IndustryBiotechnology
IPO DateDec 11, 2020
CEOLaurent Levy
Employees98
Stock ExchangeNASDAQ
Ticker SymbolNBTX
Full Company Profile

Financial Performance

In 2020, Nanobiotix's revenue was 2.51 million, a decrease of -1.14% compared to the previous year's 2.54 million. Losses were -33.59 million, -34.03% less than in 2019.

Financial numbers in millions EURFinancial Statements

News

NANOBIOTIX Provides Third Quarter Operational and Financial Update

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches ...

2 days ago - Business Wire

NANOBIOTIX to Present First Survival Data From Priority Head and Neck Cancer Program Among Five Presentations at the ...

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches ...

2 weeks ago - Business Wire

NANOBIOTIX Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May “Reprogram” the Tum...

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanophysics-based appro...

3 weeks ago - Business Wire

NANOBIOTIX Provides Business Update and Reports Financial Results for the First Half of 2021

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches...

1 month ago - Business Wire

Nanobiotix to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nanobiotix To Present at the 23rd Annual H.C. Wainwright Global Investment Conference

1 month ago - Business Wire

Nanobiotix Provides Second Quarter Operational and Financial Update

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTXNews--Nanobiotix (Euronext: NANO – NASDAQ: NBTX) provides second quarter operational and financial update.

3 months ago - Business Wire

Nanobiotix Starts New NBTXR3 Study In Lung Cancer Patients

Nanobiotix (NASDAQ: NBTX) initiated a new Phase 1 study evaluating NBTXR3 activated by radiation therapy (RT) for patients with non-small cell lung cancer (NSCLC) amenable to re-irradiation.  The study ...

3 months ago - Benzinga

NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTXNews--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering phy...

3 months ago - Business Wire

NANOBIOTIX to Host Virtual KOL Event Discussing Potential First-in-Class Radioenhancer NBTXR3 In Immunotherapy on Jun...

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTXNews--Regulatory News: NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechno...

4 months ago - Business Wire

Nanobiotix's Nanoparticle Technology Shows Tumor-Killing Effect in Early-Stage Head & Neck Cancer

Nanobiotix (NASDAQ: NBTX), ahead of the 2021 Annual Meeting of the American Society for Clinical Oncology meeting, has said that its nanoparticles were able to shrink tumors in about 77% of patients in ...

4 months ago - Benzinga

NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing L...

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #ASCO--Regulatory News: NANOBIOTIX (Euronext : NANO – NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-...

4 months ago - Business Wire

NANOBIOTIX Announces the Appointment of Bart Van Rhijn as Chief Financial Officer and Member of the Executive Board t...

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTXNews--Regulatory News: NANOBIOTIX (Euronext : NANO – NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering phys...

4 months ago - Business Wire

NANOBIOTIX to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTXNews--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering phy...

4 months ago - Business Wire

Nanobiotix Announces the Appointment of Dr. Gary Phillips as Chairman of the Nanobiotix Supervisory Board

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTXNews--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering phy...

4 months ago - Business Wire

CORRECTING and REPLACING Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immu...

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #ASCO--Regulatory News: Please replace the release dated May 19, 2021 with the following corrected version due to multiple revisions. NANOBIOTIX ANNOU...

5 months ago - Business Wire

Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential F...

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #ASCO--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics...

5 months ago - Business Wire

Nanobiotix to Present at the UBS Global Healthcare Virtual Conference

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTX--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics...

5 months ago - Business Wire

Nanobiotix, LianBio Ink NBTXR3 Development Pact In Asia For Solid Tumor Settings

Nanobiotix (NASDAQ: NBTX) has announced a partnership with LianBio to develop and commercialize Nanobiotix's lead product candidate NBTXR3, in Greater China (mainland China, Hong Kong, Taiwan, and Macau...

5 months ago - Benzinga

NANOBIOTIX Announces First Quarter Operational and Financial Updates

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTX--Regulatory News: NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext : NANO – NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology ...

5 months ago - Business Wire

NANOBIOTIX to Present Four Posters Including Updates From Priority Head and Neck Cancer and Immunotherapy Development...

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTXNews--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physi...

5 months ago - Business Wire

Nanobiotix Combined Shareholders Meeting to Be Held April 28, 2021

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company'') (Paris:NANO) (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneerin...

6 months ago - Business Wire

NANOBIOTIX Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-F

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches ...

6 months ago - Business Wire

NANOBIOTIX Reports Full Year 2020 Financial Results and Highlights Operational Progress

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company'), a late-stage clinical biotechnology company pioneeri...

7 months ago - Business Wire

Nanobiotix, PharmaEngine Terminate Development Pact For Radiation Therapy In APAC Region

Nanobiotix (NASDAQ: NBTX) and PharmaEngine Inc have agreed to terminate the license and collaboration agreement announced in August 2012. The agreement provided PharmaEngine exclusive rights to further ...

7 months ago - Benzinga

NANOBIOTIX and PharmaEngine Mutually Agree to Conclude Collaboration

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a clinical-stage biotechnology company pioneering physics-based approaches to ...

7 months ago - Business Wire